Holen Sie sich die Stockscreener-App
28.00
0.72%
0.20
Handel nachbörslich:
27.99
-0.01
-0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ARWR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$27.80
Offen:
$28
24-Stunden-Volumen:
3.36M
Relative Volume:
1.61
Marktkapitalisierung:
$3.87B
Einnahmen:
$181.74M
Nettoeinkommen (Verlust:
$-143.97M
KGV:
-20.14
EPS:
-1.39
Netto-Cashflow:
$9.60M
1W Leistung:
+25.34%
1M Leistung:
+70.06%
6M Leistung:
+63.65%
1J Leistung:
+16.76%
1-Tages-Spanne:
$27.28
$29.34
1-Wochen-Bereich:
$21.61
$29.34
52-Wochen-Spanne:
$9.57
$29.34
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Firmenname
Arrowhead Pharmaceuticals Inc
Sektor
Branche
Telefon
626-696-4702
Adresse
177 E COLORADO BLVD, PASADENA, CA
Vergleichen Sie ARWR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
28.00 | 3.55B | 181.74M | -143.97M | 9.60M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-06-05 | Eingeleitet | Goldman | Neutral |
| 2023-12-04 | Eingeleitet | BofA Securities | Buy |
| 2023-09-19 | Eingeleitet | Citigroup | Neutral |
| 2023-07-21 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-12 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2023-04-26 | Eingeleitet | SMBC Nikko | Outperform |
| 2023-04-12 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-03-21 | Eingeleitet | Bernstein | Mkt Perform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-05-11 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-01-19 | Fortgesetzt | Goldman | Buy |
| 2021-08-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-19 | Eingeleitet | Citigroup | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-05-08 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-04-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2020-03-24 | Hochstufung | SVB Leerink | Underperform → Mkt Perform |
| 2020-03-17 | Eingeleitet | Goldman | Neutral |
| 2020-01-21 | Eingeleitet | SVB Leerink | Underperform |
| 2019-12-13 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-29 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-11-27 | Bestätigt | B. Riley FBR | Buy |
| 2019-11-25 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-10-24 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-10-22 | Bestätigt | Chardan Capital Markets | Buy |
| 2019-10-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-09-07 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-09-06 | Bestätigt | Chardan Capital Markets | Buy |
| 2018-08-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-07-02 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Arrowhead Pharmaceuticals Inc Aktie (ARWR) Neueste Nachrichten
Will breakout in Arrowhead Pharmaceuticals Inc. lead to full recoveryWatch List & Real-Time Market Sentiment Reports - Newser
Will earnings trigger a reversal in Arrowhead Pharmaceuticals Inc.2025 Historical Comparison & AI Enhanced Trading Signals - Newser
Will Arrowhead Pharmaceuticals Inc. announce a stock splitWeekly Trend Report & AI Enhanced Trading Signals - khodrobank.com
Jim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money” - MSN
Arrowhead Pharmaceuticals at Cantor Global Healthcare: Strategic Moves and Market Positioning - Investing.com
Smart tools for monitoring Arrowhead Pharmaceuticals Inc.’s price actionJuly 2025 Decliners & Long-Term Growth Plans - Newser
Is Arrowhead Pharmaceuticals Inc. stock entering bullish territoryWeekly Investment Recap & Entry Point Confirmation Signals - Newser
How to forecast Arrowhead Pharmaceuticals Inc. trends using time series2025 Top Gainers & Trade Opportunity Analysis - Newser
Using data models to predict Arrowhead Pharmaceuticals Inc. stock movementShare Buyback & AI Enhanced Market Trend Forecasts - Newser
Is Arrowhead Pharmaceuticals Inc. stock risky to hold nowJuly 2025 Catalysts & Safe Capital Preservation Plans - khodrobank.com
Arrowhead Lands Billion-Dollar Biotech Deal: Stock Soars Double-Digits - Yahoo Finance
Arrowhead Pharmaceuticals at Citi’s Biopharma Conference: Strategic Insights - Investing.com
Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 01 - MarketScreener
Arrowhead Pharmaceuticals and Novartis sign global deal for siRNA therapy - MSN
Arrowhead: Upcoming Plozasiran PDUFA Review Date And Subsequent Expansion In Place (ARWR) - Seeking Alpha
Will Arrowhead Pharmaceuticals Inc. benefit from AI trendsJuly 2025 Update & AI Powered Buy and Sell Recommendations - khodrobank.com
Identifying reversal signals in Arrowhead Pharmaceuticals Inc.Earnings Recap Report & Daily Oversold Stock Bounce Ideas - Newser
Arrowhead Pharmaceuticals stock hits 52-week high at 27.35 USD - Investing.com
Arrowhead and Novartis sign agreement for ARO-SNCA - BioWorld MedTech
Arrowhead Pharmaceuticals Inc.’s volatility index tracking explainedPortfolio Profit Report & AI Forecast for Swing Trade Picks - Newser
Can a trend reversal in Arrowhead Pharmaceuticals Inc. lead to recoveryEntry Point & Smart Investment Allocation Insights - Newser
Arrowhead Pharmaceuticals Inc. stock momentum explained2025 Performance Recap & Technical Entry and Exit Alerts - Newser
Detecting price anomalies in Arrowhead Pharmaceuticals Inc. with AI2025 Fundamental Recap & High Accuracy Swing Trade Signals - Newser
Arrowhead Pharmaceuticals shares fall 1.40% premarket after announcing a global licensing and collaboration agreement with Novartis for ARO-SNCA. - AInvest
Using Ichimoku Cloud for Arrowhead Pharmaceuticals Inc. technicalsPortfolio Return Summary & Low Drawdown Momentum Ideas - Newser
Arrowhead Pharmaceuticals Inc. stock volume spike explainedJuly 2025 Retail & Daily Chart Pattern Signals - Newser
Arrowhead hits the skids due to partnership with Sarepta - MSN
Arrowhead Pharmaceuticals Inc. stock trendline breakdownJuly 2025 Short Interest & Low Risk High Win Rate Picks - Newser
Analyzing net buyer seller activity in Arrowhead Pharmaceuticals Inc.Quarterly Trade Summary & Community Consensus Trade Alerts - Newser
Stocks To Watch: Arrowhead Pharm Sees RS Rating Jump To 89 - Investor's Business Daily
Published on: 2025-09-03 01:49:11 - Newser
Using Python tools to backtest Arrowhead Pharmaceuticals Inc. strategies2025 Analyst Calls & Real-Time Buy Zone Alerts - Newser
Arrowhead Pharmaceuticals (ARWR) Soars 16.57% on $2B Novartis Deal Validating TRiM Platform - AInvest
Will Arrowhead Pharmaceuticals Inc. price bounce be sustainableJuly 2025 Market Mood & Weekly Breakout Stock Alerts - Newser
How to use Fibonacci retracement on Arrowhead Pharmaceuticals Inc.2025 Performance Recap & Technical Pattern Alert System - Newser
Published on: 2025-09-02 22:39:01 - Newser
Sarepta Sells Arrowhead Stake To Stretch Its Cash Runway; And One Stock Dives - MSN
Does Arrowhead Pharmaceuticals Inc. have strong fundamentalsJuly 2025 Summary & Weekly Top Gainers Alerts - khodrobank.com
Arrowhead, Novartis Partner In Neuroscience, An Active Deal Area For Both - insights.citeline.com
Arrowhead, Novartis in up to $2 billion deal for neuromuscular therapy license - Reuters
Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion - Investor's Business Daily
Arrowhead Pharmaceuticals inks $200 million deal with Novartis for Parkinson's disease treatment - AInvest
Arrowhead jumps on news of $2B deal with Novartis - The Pharma Letter
Applying chart zones and confluence areas to Arrowhead Pharmaceuticals Inc.Gold Moves & Precise Entry and Exit Recommendations - Newser
Arrowhead Pharmaceuticals Shares Rise After Novartis Licensing Deal Announced - MarketScreener
Arrowhead Pharmaceuticals stock surges on $200 million Novartis deal - Investing.com
Ionis reports sHTG win while Arrowhead inks Novartis deal - BioWorld MedTech
Arrowhead piques Novartis’ neuro interest with $200M upfront deal - Endpoints News
Finanzdaten der Arrowhead Pharmaceuticals Inc-Aktie (ARWR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arrowhead Pharmaceuticals Inc-Aktie (ARWR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hamilton James C | Chief Medical Officer |
Aug 15 '25 |
Sale |
20.00 |
9,389 |
187,780 |
262,122 |
| Hamilton James C | Chief Medical Officer |
Aug 13 '25 |
Sale |
20.00 |
611 |
12,220 |
271,511 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):